BioCentury
ARTICLE | Company News

Serentis Inc., Surface Therapeutics Ltd. deal

October 8, 2007 7:00 AM UTC

Serentis acquired Surface for an undisclosed amount of stock. Serentis has four compounds in preclinical testing for dermatological indications. Surface's lead product is STP-01a/ST-441 AUREOSTAT, a p...